NeuroHealing Pharmaceuticals Initiates Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease Patients
Newton, Massachusetts – February 19, 2008 NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the initiation of a Phase II clinical trial of NH004 for the treatment of sialorrhea (uncontrolled drooling) in Parkinson’s disease (PD) patients. The first patients have been enrolled, and dosing was initiated…
Details